Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project
- PMID: 25174023
- PMCID: PMC4155465
- DOI: 10.1093/jncimonographs/lgu010
Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project
Abstract
Background: Although risk factors for diffuse large B-cell lymphoma (DLBCL) have been suggested, their independent effects, modification by sex, and association with anatomical sites are largely unknown.
Methods: In a pooled analysis of 4667 cases and 22639 controls from 19 studies, we used stepwise logistic regression to identify the most parsimonious multivariate models for DLBCL overall, by sex, and for selected anatomical sites.
Results: DLBCL was associated with B-cell activating autoimmune diseases (odds ratio [OR] = 2.36, 95% confidence interval [CI] = 1.80 to 3.09), hepatitis C virus seropositivity (OR = 2.02, 95% CI = 1.47 to 2.76), family history of non-Hodgkin lymphoma (OR = 1.95, 95% CI = 1.54 to 2.47), higher young adult body mass index (OR = 1.58, 95% CI = 1.12 to 2.23, for 35+ vs 18.5 to 22.4 kg/m(2)), higher recreational sun exposure (OR = 0.78, 95% CI = 0.69 to 0.89), any atopic disorder (OR = 0.82, 95% CI = 0.76 to 0.89), and higher socioeconomic status (OR = 0.86, 95% CI = 0.79 to 0.94). Additional risk factors for women were occupation as field crop/vegetable farm worker (OR = 1.78, 95% CI = 1.22 to 2.60), hairdresser (OR = 1.65, 95% CI = 1.12 to 2.41), and seamstress/embroider (OR = 1.49, 95% CI = 1.13 to 1.97), low adult body mass index (OR = 0.46, 95% CI = 0.29 to 0.74, for <18.5 vs 18.5 to 22.4 kg/m(2)), hormone replacement therapy started age at least 50 years (OR = 0.68, 95% CI = 0.52 to 0.88), and oral contraceptive use before 1970 (OR = 0.78, 95% CI = 0.62 to 1.00); and for men were occupation as material handling equipment operator (OR = 1.58, 95% CI = 1.02 to 2.44), lifetime alcohol consumption (OR = 0.57, 95% CI = 0.44 to 0.75, for >400 kg vs nondrinker), and previous blood transfusion (OR = 0.69, 95% CI = 0.57 to 0.83). Autoimmune disease, atopy, and family history of non-Hodgkin lymphoma showed similar associations across selected anatomical sites, whereas smoking was associated with central nervous system, testicular and cutaneous DLBCLs; inflammatory bowel disease was associated with gastrointestinal DLBCL; and farming and hair dye use were associated with mediastinal DLBCL.
Conclusion: Our results support a complex and multifactorial etiology for DLBCL with some variation in risk observed by sex and anatomical site.
Published by Oxford University Press 2014.
References
-
- Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2010. National Cancer Institute; Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER website April 2013. Accessed 10 May 2013.
-
- Sant M, Allemani C, Tereanu C, et al. ; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734 - PubMed
-
- Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60(6):393–408 - PubMed
-
- Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117(11):2530–2540 - PubMed
-
- Møller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation–a population-based study of 1575 cases. Br J Haematol. 2004;124(2):151–159 - PubMed
Publication types
MeSH terms
Grants and funding
- UL 1 RR024160/RR/NCRR NIH HHS/United States
- R21 CA165923/CA/NCI NIH HHS/United States
- N01-CP-ES-11027/CP/NCI NIH HHS/United States
- K23 CA102216/CA/NCI NIH HHS/United States
- CA92153/CA/NCI NIH HHS/United States
- R01 CA092153/CA/NCI NIH HHS/United States
- R01 CA087014/CA/NCI NIH HHS/United States
- CA150037/CA/NCI NIH HHS/United States
- R01 CA100555/CA/NCI NIH HHS/United States
- R01CA45614/CA/NCI NIH HHS/United States
- K22 ES011027/ES/NIEHS NIH HHS/United States
- R01CA100555/CA/NCI NIH HHS/United States
- CA62006/CA/NCI NIH HHS/United States
- N01-PC-67008/PC/NCI NIH HHS/United States
- N01 PC067009/CN/NCI NIH HHS/United States
- N02-PC-71105/PC/NCI NIH HHS/United States
- R01CA104682/CA/NCI NIH HHS/United States
- R01 DA014690/DA/NIDA NIH HHS/United States
- N01-PC-67010/PC/NCI NIH HHS/United States
- N01 PC067010/PC/NCI NIH HHS/United States
- R03 CA143947/CA/NCI NIH HHS/United States
- N01-PC-65064/PC/NCI NIH HHS/United States
- CAPMC/ CIHR/Canada
- T32 HL007152/HL/NHLBI NIH HHS/United States
- N01 PC067008/PC/NCI NIH HHS/United States
- R03 CA125831/CA/NCI NIH HHS/United States
- R01 DC014690/DC/NIDCD NIH HHS/United States
- CA143947/CA/NCI NIH HHS/United States
- R03 CA132153/CA/NCI NIH HHS/United States
- R01CA154643-01A1/CA/NCI NIH HHS/United States
- R01 CA122663/CA/NCI NIH HHS/United States
- R03 CA150037/CA/NCI NIH HHS/United States
- N01-PC-67009/PC/NCI NIH HHS/United States
- R01 CA154643/CA/NCI NIH HHS/United States
- R01 CA062006/CA/NCI NIH HHS/United States
- R01 AI050850/AI/NIAID NIH HHS/United States
- UL1 TR000135/TR/NCATS NIH HHS/United States
- R01CA122663/CA/NCI NIH HHS/United States
- N01 PC065064/PC/NCI NIH HHS/United States
- R13 CA159842 01/CA/NCI NIH HHS/United States
- N01 CO012400/CA/NCI NIH HHS/United States
- R01 CA92153-S1/CA/NCI NIH HHS/United States
- R01 CA104682/CA/NCI NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- CA165923/CA/NCI NIH HHS/United States
- P50 CA130805/CA/NCI NIH HHS/United States
- 5R01 CA69669-02/CA/NCI NIH HHS/United States
- R01 CA50850/CA/NCI NIH HHS/United States
- CA51086/CA/NCI NIH HHS/United States
- R03CA132153/CA/NCI NIH HHS/United States
- P50 CA097274/CA/NCI NIH HHS/United States
- R01 CA051086/CA/NCI NIH HHS/United States
- R01 CA14690/CA/NCI NIH HHS/United States
- R01 CA045614/CA/NCI NIH HHS/United States
- R01CA087014/CA/NCI NIH HHS/United States
- P50 CA97274/CA/NCI NIH HHS/United States
- N01-CO-12400/CO/NCI NIH HHS/United States
- U01 CA118444/CA/NCI NIH HHS/United States
- N01-CP-95618/CP/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
